INTRODUCTION {#s1}
============

Esophageal cancer, mainly including squamous cell carcinoma and adenocarcinoma, is the sixth leading cause of cancer-related death and the eighth most common cancer worldwide \[[@R1], [@R2]\]. It is considered as a serious malignancy with respect to its extremely aggressive histopathological features and poor survival rate \[[@R3]\]. Esophageal squamous cell carcinoma (ESCC), which mainly occurs in an area referred to the "esophageal cancer belt" that extends from northeast China to the Middle East \[[@R4]\], constitutes the vast majority of cases (more than 90%) \[[@R5], [@R6]\]. Dietary and environmental factors, such as smoking, alcohol consumption, obesity, chronic irritation and high levels of nitrates in the soil and drinking water, are strongly believed to be associated with the occurrence of ESCC \[[@R1], [@R7]\]. Currently, surgical removal remains the most commonly employed treatment for patients with ESCC. However, the success of surgery strongly depends on early diagnosis. Current reliable diagnostic biomarkers are very limited in clinic \[[@R8]\]. With the increasing understanding of genetic and epigenetic mechanisms of the carcinogenesis, many studies indicated that highly sensitive and specific molecular biomarkers would help to optimize the clinical management of esophageal carcinomas and improve patient outcomes.

DNA methylation, as a gene silencing mechanism, plays essential roles in several developmental and cellular processes such as transcription, embryonic development, X-chromosome inactivation and genomic imprinting\[[@R9]-[@R11]\]. In mammals, DNA methylation occurs almost exclusively at the 5′-carbon position of cytosine residues within CpG pairs, and has a profound effect on gene expression\[[@R12]\]. The methylation of gene promoter region inhibits the binding of some transcription factors, which usually contain a methylated-DNA binding domain, resulting in transcriptional repression. Many tumor suppressor genes (TSGs), such as CDKN2A, FHIT, MGMT, RASSF1A, CDH1 and APC, have been reported to be silenced by promoter hypermethylation in the development of breast cancer \[[@R13]\], lung cancer\[[@R14], [@R15]\], thymic epithelial tumors\[[@R16]\], colorectal cancer\[[@R17], [@R18]\] and ESCC \[[@R19]\]. On the other hand, some of the oncogenes, such as GADD45A, were abnormally activated by hypomethylated changes, contributing to the occurrence of ESCC \[[@R20], [@R21]\].

Although previous studies have provided many clues to understand the relationship between DNA methylation and gene regulation in the development of ESCC, the information is still very limited. In order to acquire quantitative and qualitative information on DNA methylation, a wide range of approaches have been developed. The high-throughput sequencing (or next-generation sequencing) technologies has dramatically improved sequencing capabilities through the massive parallelization of reactions on millions of DNA fragments at once\[[@R22]\]. Methylated DNA immunoprecipitation (MeDIP) is a large-scale purification technique used for enrichment of methylated DNA sequences via an antibody against 5-methylcytosine (5-mC). Therefore, a novel method termed methylated DNA immunoprecipitation sequencing (MeDIP-Seq) has emerged as an advantageous tool for identifying methylated CpG-rich sequences much faster than ever before\[[@R23]\].

To investigate the genome-wide profiling of DNA methylation and gene expression in ESCC, MeDIP-Seq and quantitative measurements of transcriptomes (RNA-Seq) were performed in this study. Owing to the tremendous progress in next-generation sequencing technology, MeDIP-Seq and RNA-Seq can offer higher resolution, less noise and greater coverage results \[[@R23]-[@R25]\]. The combination of MeDIP-Seq and RNA-Seq may provide more information about genome-wide epigenetic regulation in gene expression and will bring new insight on the DNA methylation in the development of ESCC.

RESULTS {#s2}
=======

High-throughput MeDIP sequencing analysis {#s2_1}
-----------------------------------------

We isolated genomic DNA from 4 pairs of ESCC and NE tissue samples, and then put equal amounts of genomic DNA of 4 individuals into one pool for each group (the ESCC group and the NE group). The MeDIP-Seq was conducted on the two groups using the Hiseq 2000 sequencing system, which provided high accuracy and unprecedented output.

In total, we obtained about 86 million clean 49-bp reads after sequencing. And the unique mapping rates satisfied the requirements. In the ESCC group, 90.89 % of the reads could be mapped to human genome and 73.26% were uniquely mapped to human genome. While in NE group, 88.85% of the reads could be mapped to the human genome and 68.43% could be uniquely mapped to the human genome (Table [1](#T1){ref-type="table"} and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). To understand the global DNA methylation status in ESCC, we directly compared the overall distribution of reads at 1kb resolution level. The CpG o/e values were calculated to reflect the CpG density of specific regions\[[@R26]\]. As expected, both hypermethylated and hypomethylated changes were found in ESCC samples compared to NE (Figure [1](#F1){ref-type="fig"}). Model-based analysis of ChIP-Seq (MACS)\[[@R27]\] identified 286,272 and 260,746 regions (peaks) from the ESCC and NE MeDIP-Seq data, respectively. The average length of peaks varied from 1,095 bp (ESCC) to1, 124 bp (NE). Peak-based differential analysis was conducted for gene elements that were covered by two groups and exhibited a greater than 2-fold change in methylation and a p-value of less than 0.01 (Table [2](#T2){ref-type="table"} and [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}).

###### Number of reads generated by MeDIP-seq for each group

  Sample group   Total number of reads   Total number of mapped reads   Mapping rate(%)   Total number of unique mapped reads   Unique mapping rate (%)
  -------------- ----------------------- ------------------------------ ----------------- ------------------------------------- -------------------------
  ESCC           85,714,286              77,904,067                     90.89             62,791,726                            73.26
  NE             85,714,286              76,156,660                     88.85             58,652,189                            68.43

###### Number of peak-related differences in gene methylation identified between groups

  \# of genes     NE vs ESCC (up-regulated)   NE vs ESCC (down-regulated)
  --------------- --------------------------- -----------------------------
  Upstream 2K     960                         52
  5′UTR           322                         28
  CDS             2071                        193
  Intron          6702                        1455
  3′UTR           635                         40
  Downstream 2K   864                         42

![Distribution of reads varies CpG density\
**A.** Distribution of reads varies CpG o/e value. The x axis indicates the range of CpG o/e values and the y axis indicates the proportion of reads in a specific range. CpG o/e value can reflect the CpG density of a specific region. DNA hypermethylation may have lower CpG o/e value, while hypomethylation maintain high o/e value. **B.** Overall distribution of reads at 1kb resolution level varies CpG density. The x axis indicates the CpG density and the y axis indicates the proportion of reads.](oncotarget-07-4507-g001){#F1}

The main goal of this study was to identify local differentially methylated regions (DMRs) between ESCC and NE groups in a genome-wide level. In total we identified 26,081 DMRs, 87.6% of them were hypermethylated and 12.4% of them were hypomethylated relative to NE group. The distribution of the DMRs showed that most of the DMRs were located at gene body (Table [3](#T3){ref-type="table"}). Gene ontology (GO) analysis of genes with DMRs was also conducted, for both hypermethylated and hypomethylated genes ([Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}).

###### Number of DMRs in six characteristic genomic areas

  Genomic areas   Hypermethylated   Hypomethylated
  --------------- ----------------- ----------------
  Upstream 2K     1094              64
  5′UTR           378               32
  CDS             2792              224
  Intron          16932             2824
  3′UTR           727               47
  Downstream 2K   915               52

Validation of the MeDIP-Seq results {#s2_2}
-----------------------------------

Four genes were selected to validate the results of the MeDIP-Seq: MLH1, CDH5, TWIST1 and CDX1. We mainly focus on the DMRs located at promoter region, which may contribute the regulation of gene expression. The starting and ending point of the DMRs of these four genes, the CG sites and the primers are showed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

Of the18 CpG sites from MLH1 DMR region, 9 continuous clustered CpG loci (−52, −54, −64, −71, −88, −102, −111, −142, −148) were identified to be significantly hypermethylated in ESCC samples than that in NE samples (0.707±0.133 vs 0.302±0.09, p\<0.001; Fig. [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Compared to NE, CDH5 DMR region were also significantly hypermethylated in ESCC samples (0.663±0.086 vs 0.247±0.084, p\<0.001; Fig. [2A](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}).

![DNA methylation at genes locus\
**A, B** and **C.** Compare to NE group, the MLH1 and CDH5 were significantly hypermethylated in ESCC samples (0.707±0.133 vs 0.302±0.09, p\<0.001; 0.663±0.086 vs 0.247±0.084, p\<0.001). **A, D** and **E.** Compare to NE group, TWIST1 and CDX1 were significantly hypomethylated in ESCC samples (0.544±0.241 vs 0.752±0.117, p\<0.001; 0.475±0.194 vs 0.693±0.102, p\<0.001). **F.** DNA methylation level of MLH1, TWIST1 and CDX1 were related to TNM stage.](oncotarget-07-4507-g002){#F2}

There were no significant differences in the DNA methylation status of all the 13 CpG sites of the TWIST1 DMR region (−1500bp∼-1320), however, 6 continuous clustered CpG loci (−1398, −1418, −1424, −1427, −1430, −1453) showed hypomethylated changes in ESCC samples (0.544±0.241 vs 0.752±0.117, p\<0.001; Fig. [2A](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Moreover, significant hypomethylation of CDX1 DMR region were also found in the ESCC group compared to NE group (0.475±0.194 vs 0.693±0.102, p\<0.001; Fig. [2A](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}).

The DNA methylation level of MLH1, TWIST1 and CDX1 were related to TNM stage (MLH1: p\<0.001; CDH5: p=0.636; TWIST1: p=0.038; CDX1: p=0.002; Fig. [2F](#F2){ref-type="fig"}). There was no significant correlation between DNA methylation levels and tumor histological differentiation.

Identification of gene expression by RNA-Seq {#s2_3}
--------------------------------------------

RNA-Seq was performed to investigate the genome-wide expression changes in ESCC and adjacent NE. The sequencing provided us about 26.5 million clean 49-bp reads. In ESCC, 88.28% of the reads were mapped to the human genomic sequence with no more than two mismatches and 82.66 % were uniquely mapped to the human genome, while in NE library, 88.78 % of the reads were mapped to the human genomic sequence and 83.92 % could be uniquely mapped (Table [4](#T4){ref-type="table"}). For genes with multiple transcripts, we chose the longest transcript for further analysis.

###### Number of reads generated by RNA-seq for each group

  Sample group   Total number of reads   Total number of mapped reads   Mapping rate(%)   Total number of unique mapped reads   Unique mapping rate (%)
  -------------- ----------------------- ------------------------------ ----------------- ------------------------------------- -------------------------
  ESCC           26,708,458              23,578,386                     88.28             22,077,327                            82.66
  NE             26,552,622              23,573,912                     88.78             22,283,765                            83.92

Gene expression was initially estimated by calculating the density of uniquely mapped reads as "reads per kilo base of exon model per million mapped reads" (RPKM). Differentially expressed genes (DEGs) were identified by using a threshold of 0.1 % false discovery rate (FDR) and \|log2ratio\|≥1 (ratio = treated/control RPKM). A total of 6150 genes (3423 up-regulated and 2727 down-regulated) were differentially expressed between ESCC and NE groups (Fig. [3](#F3){ref-type="fig"} and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). To study biological functions, GO analysis was performed on the differentially expressed genes with p values \< 0.005\[[@R28]\]. The significant GO terms showed that these DEGs were related to many biological processes and molecular functions (Fig. [4](#F4){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Most of these terms were closely related to the cell differentiation, adhesion, cell proliferation, response to DNA damage, or DNA replication. Among these DEGs, we identified many previously described tumor-related genes, such as MLH1, CDKN2A, DAPK1, CDX1, TWIST1, CDH5 and CXCL5 \[[@R29]-[@R33]\]. The KEGG pathway analysis showed that these DEGs were involved in 197 pathways. Among these pathways, 33 showed significant (Q\<0.05) enrichment of DEGs in ESCC (Table [5](#T5){ref-type="table"}). Furthermore, the quantitative real time RT-PCR (qRT-PCR) was performed to validate the results of RNA-Seq. In total the expression of 14 genes were investigated in ESCC and NE samples. A high level of concordance between qRT-PCR results and RNA-Seq data confirmed the RNA-Seq results were acceptable (r=0.889, p\<0.001; Fig. [5A](#F5){ref-type="fig"}).

###### Significantly enriched pathways for DEGs

  Pathway                                                  DEGs with pathway annotation   All genes with pathway annotation   Q value        Pathway ID
  -------------------------------------------------------- ------------------------------ ----------------------------------- -------------- ------------
  Dilated cardiomyopathy                                   66                             108                                 2.611394e-09   ko05414
  Hypertrophic cardiomyopathy (HCM)                        61                             101                                 1.971738e-08   ko05410
  Cell adhesion molecules (CAMs)                           74                             134                                 1.292208e-07   ko04514
  Calcium signaling pathway                                99                             193                                 1.515844e-07   ko04020
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)   48                             80                                  8.359827e-07   ko05412
  ECM-receptor interaction                                 46                             84                                  4.016593e-05   ko04512
  Vascular smooth muscle contraction                       62                             129                                 0.0003407075   ko04270
  Focal adhesion                                           93                             208                                 0.0003635684   ko04510
  Long-term potentiation                                   37                             70                                  0.00056412     ko04720
  Viral myocarditis                                        38                             73                                  0.0007063471   ko05416
  Axon guidance                                            60                             129                                 0.001193845    ko04360
  Melanogenesis                                            50                             104                                 0.001217776    ko04916
  Cytokine-cytokine receptor interaction                   115                            277                                 0.002342581    ko04060
  Glycine, serine and threonine metabolism                 18                             31                                  0.003986321    ko00260
  Hematopoietic cell lineage                               46                             99                                  0.004332282    ko04640
  Type I diabetes mellitus                                 23                             43                                  0.004977168    ko04940
  Phosphatidylinositol signaling system                    36                             76                                  0.00748928     ko04070
  Steroid biosynthesis                                     11                             17                                  0.007951011    ko00100
  Regulation of actin cytoskeleton                         94                             230                                 0.009258026    ko04810
  Prion diseases                                           22                             43                                  0.01161543     ko05020
  Leukocyte transendothelial migration                     51                             118                                 0.0152988      ko04670
  Bladder cancer                                           23                             47                                  0.01890428     ko05219
  p53 signaling pathway                                    34                             75                                  0.01990306     ko04115
  Cardiac muscle contraction                               42                             96                                  0.02082785     ko04260
  Pathways in cancer                                       135                            351                                 0.02250529     ko05200
  Renin-angiotensin system                                 10                             17                                  0.02715161     ko04614
  DNA replication                                          18                             36                                  0.02807702     ko03030
  Arginine and proline metabolism                          25                             54                                  0.03205055     ko00330
  Cell cycle                                               61                             150                                 0.03473822     ko04110
  Basal cell carcinoma                                     25                             55                                  0.04061275     ko05217
  Primary immunodeficiency                                 17                             35                                  0.04385614     ko05340
  PPAR signaling pathway                                   31                             71                                  0.04405247     ko03320
  N-Glycan biosynthesis                                    22                             48                                  0.04797281     ko00510

![Whole genome expression profiles\
**A.** Differentially expressed gene numbers between ESCC and NE. The y axis indicates the gene numbers. **B.** Comparison of gene expression level between ESCC and NE. Red dots represent transcripts more prevalent in ESCC, green dots show those down-regulated genes in ESCC and black dots indicate gene expression did not change significantly.](oncotarget-07-4507-g003){#F3}

![GO analysis showed that these DEGs related to many biological processes and molecular functions\
**A.** and **B.** DEGs involved in many biological processes. **C.** DEGs correlated with molecular functions.](oncotarget-07-4507-g004){#F4}

![Results of correlation analysis\
**A.** High level of concordance between qRT-PCR results and RNA-Seq data confirmed the RNA-Seq results were acceptable (r=0.889, p\<0.001). **B, C** and **D.** Correlation analyses showed that the DNA methylation levels of MLH1, TWIST1 and CDX1 were negatively correlated with their mRNA expression (MLH1: r=−0.776, p\<0.001; TWIST1: r=−0.515, p\<0.001; CDX1: r=−0.649, p\<0.001).](oncotarget-07-4507-g005){#F5}

Association of DNA methylation changes, differential gene expression and clinical pathological features {#s2_4}
-------------------------------------------------------------------------------------------------------

The qRT-PCR results showed that the mRNA expression of MLH1, CDH5, ITIH5, CRABP1, CDKN2A, CDO1 and FHIT were significantly down-regulated in ESCC samples compared to NE samples. In contrast, the mRNA expression of TWIST1, CXCL5, GADD45A, WNT3A and CDX1 was significantly up-regulated in ESCC samples than that in NE ([Supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). Correlation analyses showed that the DNA methylation levels of MLH1, TWIST1 and CDX1 were negatively correlated with their mRNA expression (MLH1: r=−0.776, p\<0.001; TWIST1: r=−0.515, p\<0.001; CDX1: r=−0.649, p\<0.001; Fig. [5B](#F5){ref-type="fig"}, [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}).

For survival analysis, patients were grouped into low methylation or high methylation groups according to their methylation Z scores. Survival analysis showed that the aberrant methylation of MLH1 significantly related to patients' survival (p=0.001; Fig. [6](#F6){ref-type="fig"}).

![Results of survival analysis\
**A.** Survival analysis showed that the aberrant methylation of MLH1 significantly related to patient survival (p=0.001). **B, C.** and **D.** DNA methylation level of CDH5, TWIST1 and CDX1 did not correlated with patient survival (p=0.797; p=0.324 and p=0.133).](oncotarget-07-4507-g006){#F6}

DISCUSSION {#s3}
==========

In this study, we used the high-throughput MeDIP-Seq and RNA-Seq to examine whole-genome DNA methylation patterns and messenger RNA transcriptome in a total of 4 pairs of ESCC samples and NE samples. Our findings provided a comprehensive, detailed picture of DNA methylation patterns and gene expression levels in patients with ESCC. The DMRs identified by MeDIP-Seq spanned almost the entire genome with sufficient depth and high resolution, and the number of DMRs was much greater than that detected by traditional approaches, indicating that this method represents an effective approach for DNA methylome studies \[[@R22], [@R23]\]. Moreover, the bisulfite sequencing analysis of MLH1, CDH5, TWIST1 and CDX1 were in accordance with the MeDIP-Seq results. It also proved the high accuracy of the high-throughput sequencing technique.

With the increasing availability and applications of high-throughput sequencing methods, more and more studies have reported the methylation of tissue-specific genes mainly occurred within the gene body instead of the 5′promoters \[[@R34]-[@R36]\]. Our study also found that most of the DMRs occurred within the gene body, only small proportion of DMRs located at the 5′promoter region. Moreover, the great number of uniquely mapped reads located at the intronic region, indicating the DNA methylation in introns may have important regulatory functions.

To understand the global DNA methylation pattern in ESCC, we compared the overall distribution of reads between ESCC and NE groups. As expected, both hypermethylated and hypomethylated changes were observed in ESCC samples compared to NE (Fig. [1](#F1){ref-type="fig"}). The similar results have been shown in previous studies \[[@R37], [@R38]\].

In total of 6150 differentially expressed genes were identified by RNA-Seq in our study. The results of RNA-Seq were confirmed by qRT-PCR from validation of a number of randomly selected genes. GO analysis revealed these DEGs were significantly enriched in many cell related process and molecular functions, such as cell differentiation, apoptosis, adhesion and proliferation. Aberrant expressions of some of these genes were previously reported to be important in the development of ESCC \[[@R28], [@R39], [@R40]\]. Pathway analysis highlighted many pathways which were closely related to the carcinogenesis of ESCC, such as cell adhesion molecules, p53 and PPAR signaling pathways, providing new clues for understanding the molecular mechanisms of ESCC pathogenesis.

In light of previously described effects of DNA methylation on promoters\[[@R41]\], we selected DMRs from upstream 2kbp of transcription start site to validate the MeDIP-Seq results. According to GO analysis and pathway analysis, DMRs were identified in genes associated with cell cycle, adhesion, apoptosis and many biological pathways, which were closely correlated with carcinogenesis. As such, we selected four genes for further study: TWIST1, CDX1, MLH1 and CDH5.

TWIST1 is one of the epithelial-to-mesenchymal transition (EMT) inducer prototypes, which lead to epithelial cells lose their adhesion properties and acquire mesenchymal features allowing their migration and invasion \[[@R42]\]. The overexpression of TWIST1 has been reported in previous studies showing that it could be a biomarker for tumor progression and metastasis \[[@R43]-[@R46]\]. Interestingly, promoter hypermethylation of TWIST1 was also observed in the development of colorectal cancer, vulvar cancer and tonsillar squamous cell carcinoma \[[@R47]-[@R49]\]. Recently, Galvan et al. reported strong inverse correlations between TWIST1 methylation and stromal expression of TWIST1 in colon cancer \[[@R50]\]. Wong and colleagues reported promoter-specific hypomethylation of TWIST1 was strongly associated with gene overexpression \[[@R51]\], indicating the promoter methylation may regulate the TWIST1 expression. Our MeDIP-Seq results, for the first time, identified a DMR (from −1010 to −1715) in upstream 2K of TWIST1. Significant hypomethylated changes of 6 continuous clustered CpG loci (−1398, −1418, −1424, −1427, −1430, −1453) were identified in this region. Overexpression of TWIST1 was detected in both RNA-Seq data and qRT-PCR validation test, with adverse correlation with DNA hypomethylation. Nevertheless, survival analysis did not found significant correlation between overexpression or methylation of TWIST1 and patients' survival. Our results indicated that the DNA hypomethylation, to some degree, has regulatory function for the expression of TWIST1 in ESCC.

CDX1 was previously described as an oncogene since it regulated Ras, Wnt/β-catenin and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells \[[@R52]\]. Recent studies showed that CDX1 expression was down-regulated by promoter hypermethylation in colon cancer \[[@R31], [@R53]\], whereas a subset of colon cancers may express increased levels of CDX1 mRNA and protein \[[@R54]\]. Our results showed that the hypomethylation of CDX1 was related to the gene overexpression in ESCC samples, which indicated that the CDX1 might have oncogenic potential in the development of ESCC \[[@R55]\].

The silencing and promoter hypermethylation of tumor suppressor gene MLH1 and CDH5 have been reported in various cancers \[[@R56]-[@R59]\]. Deng and colleagues reported that MLH1 silencing by methylation is region specific. The loss of expression of MLH1 was correlated with the proximal region (from −322 to +56), but not the distal region (from −796 to −547) \[[@R60]\]. In our study, the identified MLH1 DMR (from −250 to −10) also located at proximal region. In validation test, hypermethylation in this region was detected and related to gene silencing. Moreover, the survival analysis showed that the methylation of MLH1 significantly correlated with patient survival, indicating the MLH1 might play important role in the carcinogenesis of ESCC. Together, our results show that genome-wide aberrant DNA methylation of cancer-associated genes may be involved in the pathogenesis of ESCC.

MATERIALS AND METHODS {#s4}
=====================

Tissue samples {#s4_1}
--------------

Fresh frozen ESCC samples and paired adjacent normal esophageal (NE) tissue samples (healthy surrounding esophageal tissue more than 5 cm away from tumor) were obtained from 47 ESCC patients at the Second Xiangya Hospital of Central South University, Changsha, China. The 25 male and 22 female patients ranged between 45 and 71 years of age (mean 58.9 ± 6.9 years) and all had undergone ESCC surgery between April 2010 and August 2013. None of the patients had received preoperative treatments, such as chemotherapy or radiotherapy. Control samples were histologically and pathologically confirmed as healthy esophageal tissues, while all tumor samples were confirmed as ESCC, and staged according to the TNM system. Only samples with a tumor cell content of more than 80% were included in this study. A summary of clinical and pathological characteristics of patients included in this study is presented in Table [6](#T6){ref-type="table"}.

###### Characteristics of 47 patients with ESCC

  Patient No.   Gender/age (years)   Alcohol History   TNM Stage   Histological Differentiation
  ------------- -------------------- ----------------- ----------- ------------------------------
  1             F/60                 No                IIb         Moderate
  2             M/56                 Yes               IIb         Moderate
  3             M/56                 Yes               IIIa        Moderate
  4             F/48                 No                IIIa        Moderate
  5             F/45                 Yes               Ia          Low
  6             M/56                 Yes               Ib          Moderate
  7             F/67                 No                Ib          High
  8             M/67                 Yes               Ib          Moderate
  9             M/59                 Yes               Ib          High
  10            M/65                 Yes               Ib          Moderate
  11            M/49                 No                Ib          High
  12            F/52                 Yes               Ib          Moderate
  13            M/53                 No                IIb         Moderate
  14            F/65                 No                IIb         Low
  15            M/51                 Yes               IIb         Moderate
  16            F/51                 No                IIb         Moderate
  17            F/69                 Yes               IIb         Moderate
  18            M/68                 Yes               IIIb        Moderate
  19            F/59                 No                IIIb        High
  20            F/48                 No                Ia          Low
  21            F/71                 No                IIa         Moderate
  22            F/64                 No                IIa         Moderate
  23            M/71                 Yes               IIa         Moderate
  24            M/64                 Yes               IIb         High
  25            F/59                 Yes               IIb         High
  26            M/71                 Yes               IIb         High
  27            M/61                 Yes               IIb         Moderate
  28            F/60                 No                IIb         Low
  29            M/65                 Yes               IIb         High
  30            F/58                 No                IIb         Moderate
  31            M/58                 No                IIb         High
  32            M/59                 Yes               IIIa        Moderate
  33            M/59                 No                IIIa        Low
  34            F/71                 Yes               IIIa        Moderate
  35            M/52                 Yes               IIIa        Moderate
  36            F/48                 No                IIIa        Low
  37            F/57                 Yes               IIIa        High
  38            F/62                 No                IIIa        High
  39            M/62                 Yes               IIIa        Low
  40            F/50                 Yes               IIIb        High
  41            F/62                 No                IIIb        High
  42            M/48                 Yes               IIIb        High
  43            M/55                 Yes               IIIc        High
  44            M/61                 Yes               IIIc        Low
  45            F/60                 No                IIIc        High
  46            M/62                 Yes               IIIc        Moderate
  47            M/65                 Yes               IV          High

This study was approved by the Human Ethics Committee of the Second Xiangya Hospital, Central South University. Written informed consents were obtained from all participants.

Genomic DNA and total RNA isolation and pooling {#s4_2}
-----------------------------------------------

Genomic DNA was isolated from ESCC and NE tissue samples using Qiagen DNeasy Kits (Qiagen, Germany) according to the manufacturer\'s instructions. For MeDIP-Seq, an equal quantity of DNA of four parallel individuals (Patient No.1, 2, 3 and 4) from ESCC and NE groups was then pooled respectively.

Total RNA was isolated from each sample with TRIzol Reagent (Invitrogen, USA) according to the manufacturer\'s instructions, then treated with RNase-free DNase I for 30 min at 37°C(New England BioLabs) to remove residual DNA. The integrity of total RNA was checked using an Agilent Technologies 2100 Bioanalyzer, and all samples had an RNA Integrity Number (RIN) value greater than eight. Pooling of the RNA samples was the same as the DNA pooling, using for RNA-Seq.

MeDIP-Seq, RNA-Seq and data analysis {#s4_3}
------------------------------------

The detection and analysis of MeDIP-Seq and RNA-Seq were performed as described previously \[[@R61], [@R62]\]. Pathway enrichment analysis was based on KEGG database (<http://www.genome.jp/kegg/>), and Q value was used for determining the threshold of significance in multiple test and analysis. Pathways with a Q value \<0.05 are considered significantly enriched in differentially expressed or modified genes ([Supplementary Fig. S5](#SD1){ref-type="supplementary-material"}).

Bisulfite conversion and sequencing {#s4_4}
-----------------------------------

Bisulfite conversion was performed using the EpiTect Bisulfite Kit (Qiagen, Germany), according to manufacturer\'s instruction. Fragments about 250 bp flanking each side of the loci of MLH1, CDH5, TWIST1 and CDX1 were amplified by PCR. The fragments were cloned into pGEM-T vectors (Promega, USA) and independent clones were sequenced for each of the amplified fragments\[[@R63]\]. The primers designed for the BSP were showed in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

Real-time quantitative RT-PCR {#s4_5}
-----------------------------

Real-time quantitative RT-PCR was performed using a Prism 7500 Sequence Detection System (ABI, USA) and mRNA levels were quantified using the SYBR®Premix Ex Taq™(Takara Bio Inc., Dalian, China). A dilution series of sample RNA was also included to generate a standard curve used to calculate the relative concentrations of transcript present in each sample. Negative controls (in which water was substituted for RNA) were run for each sample. β-actin was also amplified and used as a loading control. Specific primers used for amplification were showed in [Supplementary Table S2](#SD2){ref-type="supplementary-material"}.

Statistical analysis {#s4_6}
--------------------

To evaluate the methylation level of individual genes, methylation for each gene among the patients was standardized by the Z score method\[[@R64]\]. Data was analyzed using SPSS 20.0 software (SPSS Inc., Chicago, USA) and are presented as the mean ± standard deviation (SD). Student\'s t-test was used to compare continuous variables and Pearson\'s correlation test was used for correlation analyses. Overall survival was calculated by Log-rank tests and the Kaplan-Meier test was used to generate survival curves. P values of less than 0.05 were considered significant.

SUPPLEMENTARY FIGURES AND TABLES {#s5}
================================
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